See more : LAND Co., Ltd. (8918.T) Income Statement Analysis – Financial Results
Complete financial analysis of Standard BioTools Inc. (FLDM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Standard BioTools Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Arcus ASA (ARCUS.OL) Income Statement Analysis – Financial Results
- Colan Totte.Co.,Ltd. (7792.T) Income Statement Analysis – Financial Results
- Apator S.A. (APT.WA) Income Statement Analysis – Financial Results
- Hefei Urban Construction Development Co., Ltd (002208.SZ) Income Statement Analysis – Financial Results
- Sharps Compliance Corp. (SMED) Income Statement Analysis – Financial Results
Standard BioTools Inc. (FLDM)
About Standard BioTools Inc.
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.40M | 130.58M |
| Cost of Revenue | 55.89M | 60.90M | 61.21M | 54.82M | 52.96M | 51.32M | 49.96M | 46.01M | 46.63M | 42.85M | 20.08M | 15.33M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M | 53.32M |
| Gross Profit | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.10M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M | 77.27M |
| Gross Profit Ratio | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.80% | 45.50% | 51.70% | 56.66% | 59.17% |
| Research & Development | 25.95M | 38.50M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.42M | 39.26M | 43.42M | 19.73M | 16.60M | 13.94M | 13.01M | 12.32M | 14.02M | 14.39M | 15.59M | 37.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.54M | 114.76M | 98.89M | 97.90M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.06M | 38.48M | 31.30M | 23.55M | 19.65M | 22.51M | 12.90M | 9.70M | 98.89M |
| Other Expenses | 0.00 | -12.31M | 7.63M | 507.00K | 1.43M | 637.00K | 385.00K | -1.17M | -1.16M | -857.00K | 502.00K | -189.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.89M |
| Operating Expenses | 113.49M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.79M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M | 144.73M |
| Cost & Expenses | 169.38M | 214.15M | 198.04M | 189.18M | 169.08M | 161.13M | 160.30M | 177.64M | 168.85M | 157.60M | 87.87M | 70.41M | 58.43M | 48.13M | 43.45M | 44.89M | 30.80M | 28.06M | 198.04M |
| Interest Income | 0.00 | 4.33M | 291.00K | 307.00K | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.00K | 37.00K | 766.00K | 1.14M | 565.00K | 0.00 |
| Interest Expense | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14.00K | 628.00K | 3.10M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M | -3.82M |
| Depreciation & Amortization | 15.18M | 15.03M | 16.07M | 17.94M | 15.81M | 16.50M | 18.30M | 17.94M | 16.12M | 4.06M | 2.55M | 1.48M | 1.06M | 1.50M | 1.94M | 1.97M | 2.14M | 1.46M | 0.00 |
| EBITDA | -54.46M | -173.57M | -43.77M | -34.61M | -46.62M | -31.03M | -39.68M | -56.42M | -32.87M | -38.50M | -13.82M | -16.78M | -18.14M | -13.52M | -14.67M | -26.12M | -20.91M | -19.83M | -67.46M |
| EBITDA Ratio | -51.21% | -115.87% | -33.89% | -25.05% | -29.51% | -27.40% | -38.62% | -54.02% | -34.16% | -32.58% | -19.15% | -32.06% | -33.84% | -38.92% | -63.20% | -174.69% | -278.32% | -306.96% | -51.66% |
| Operating Income | -76.60M | -116.21M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M | -67.46M |
| Operating Income Ratio | -72.03% | -118.64% | -51.66% | -36.94% | -44.22% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.50% | -323.38% | -338.59% | -51.66% |
| Total Other Income/Expenses | 2.40M | -76.72M | 3.80M | -3.07M | -14.87M | -13.26M | -5.44M | -6.99M | -4.64M | -5.87M | 2.26M | -817.00K | -3.74M | -2.25M | -1.14M | -103.00K | -1.82M | -1.89M | 3.80M |
| Income Before Tax | -74.20M | -192.93M | -63.66M | -54.10M | -66.71M | -61.42M | -63.80M | -80.18M | -54.79M | -57.71M | -15.69M | -18.89M | -22.30M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M | -63.66M |
| Income Before Tax Ratio | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.40% | -368.13% | -48.75% |
| Income Tax Expense | 452.00K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137.00K | 136.00K | 166.00K | 83.00K | -50.00K | -147.00K | 105.00K | 194.00K | -4.42M |
| Net Income | -74.66M | -190.10M | -59.24M | -53.02M | -64.79M | -59.01M | -60.54M | -75.99M | -53.32M | -52.83M | -15.82M | -19.02M | -22.47M | -16.90M | -19.13M | -29.50M | -25.45M | -23.55M | -59.24M |
| Net Income Ratio | -70.21% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% | -45.36% |
| EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| EPS Diluted | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 | 0.00 |
| Weighted Avg Shares Out | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
| Weighted Avg Shares Out (Dil) | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M | 0.00 |
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fluidigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2020 - FLDM
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fluidigm Corporation (FLDM)
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fluidigm Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fluidigm Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
FLDM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 20, 2020 in the Class Action Filed on Behalf of Fluidigm Corporation Limited Shareholders
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fluidigm Corporation (FLDM)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fluidigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2020 - FLDM
Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
FLDM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 20, 2020 in the Class Action Filed on Behalf of Fluidigm Corporation Limited Shareholders
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fluidigm Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2020 - FLDM
Source: https://incomestatements.info
Category: Stock Reports